Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MIA, a novel serum marker for progression of malignant melanoma
Autore:
Bosserhoff, AK; Lederer, M; Kaufmann, M; Hein, R; Stolz, W; Apfel, R; Bogdahn, U; Buettner, R;
Indirizzi:
Univ Regensburg, Sch Med, Inst Pathol, Dept Pathol, D-93042 Regensburg, Germany Univ Regensburg Regensburg Germany D-93042 , D-93042 Regensburg, Germany Univ Regensburg, Sch Med, Dept Dermatol, D-93042 Regensburg, Germany Univ Regensburg Regensburg Germany D-93042 , D-93042 Regensburg, Germany Univ Regensburg, Sch Med, Dept Neurol, D-93042 Regensburg, Germany Univ Regensburg Regensburg Germany D-93042 , D-93042 Regensburg, Germany Boehringer Mannheim GmbH, Werk Tutzing, D-82324 Tutzing, Germany Boehringer Mannheim GmbH Tutzing Germany D-82324 -82324 Tutzing, Germany Tech Univ Munich, Dept Dermatol & Allergol, D-80802 Munich, Germany Tech Univ Munich Munich Germany D-80802 llergol, D-80802 Munich, Germany
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 4A, volume: 19, anno: 1999,
pagine: 2691 - 2693
SICI:
0250-7005(199907/08)19:4A<2691:MANSMF>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
GENE; PROTEIN;
Keywords:
MIA (melanoma-inhibiting-activity); melanoma; serum marker;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
5
Recensione:
Indirizzi per estratti:
Indirizzo: Buettner, R Univ Regensburg, Sch Med, Inst Pathol, Dept Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany Univ Regensburg Franz Josef StrAllee 11 Regensburg Germany D-93042
Citazione:
A.K. Bosserhoff et al., "MIA, a novel serum marker for progression of malignant melanoma", ANTICANC R, 19(4A), 1999, pp. 2691-2693

Abstract

MIA was isolated previously as a small soluble protein secreted from malignant melanoma cell lines in vitro. Highly restricted expression patterns inmelanocytic tumors were identified in vivo. We therefore quantitated serumlevels of MIA protein by means of a non-radioactive ELISA and investigatedwhether MIA provides clinically relevant parameters in patients with malignant melanomas. Here we report enhanced MIA serum levels in 13% and 23% of patients with stage I and IP disease, respectively, and in 100% with stage III or IV disease. Response to therapy in stage IV disease correlated with changes in MIA serum levels and surgical removal of metastases led to normalization of serum values. Repeated measuring of sera from 350 patients witha history of stage I or II melanoma during follow-up, we detected 32 patients developing positive MIA values. Ar the time of serum analysis 15 of them had developed metastases and one presented with metastatic disease 6 months later. In conclusion, MIA represents a novel serum market for systemic malignant melanoma revealing the highest sensitivity and specificity among currently available markers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 05:50:45